Journal of Clinical Oncology, Vol 13, 961-968, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center

V Leblond, L Sutton, R Dorent, F Davi, MO Bitker, J Gabarre, F Charlotte, JJ Ghoussoub, C Fourcade and A Fischer
Departement d'Hematologie, Hopital Pitie-Salpetriere, Paris, France.

PURPOSE: Organ recipients are at a high risk of post-transplant lymphoproliferative disorders (PTLDs) as a complication of immunosuppressive therapy. We report the incidence, clinical presentation, pathologic findings, treatment, and outcome for 24 cases of PTLD observed at our institution. PATIENTS AND METHODS: Twenty-four (1.7%) of 1,385 organ transplant recipients developed PTLDs. Dosages of immunosuppressive drugs were reduced in 19 patients. Treatment consisted of anti-B-cell monoclonal antibodies (12 patients), and/or chemotherapy (eight patients), or surgery (two patients). RESULTS: The median time between grafting and the onset of PTLD was 210 days. Tumors were classified as monomorphic and polymorphic in nine and 15 cases, respectively. Three of 24 cases were of T-cell origin. Genotypic studies confirmed the monoclonality of the tumors in 11 cases among 14 PTLDs tested. Epstein-Barr virus (EBV) infection was associated with 70% of B-cell PTLDs tested. The overall survival duration was 5 months. Ten patients are alive and disease-free with a median follow-up time of 37 months; most were treated with anti-B-cell antibodies. Two other patients died in complete remission of unrelated causes at 33 and 38 months. CONCLUSION: Anti-B-cell monoclonal antibody therapy seems to be effective in PTLD, even in monoclonal B-cell forms, but other approaches will be necessary to improve survival further.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Knight, A. Tsodikov, D. M. Cibrik, C. W. Ross, M. S. Kaminski, and D. W. Blayney Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center J. Clin. Oncol., July 10, 2009; 27(20): 3354 - 3362. [Abstract] [Full Text] [PDF]

				E. Gonzalez-Barca, E. Domingo-Domenech, F. J. Capote, J. Gomez-Codina, A. Salar, A. Bailen, J.-M. Ribera, A. Lopez, J. Briones, A. Munoz, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease Haematologica, November 1, 2007; 92(11): 1489 - 1494. [Abstract] [Full Text] [PDF]

				J.-J. Lee, M. S. Lam, and A. Rosenberg Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation Ann. Pharmacother., October 1, 2007; 41(10): 1648 - 1659. [Abstract] [Full Text] [PDF]

				A. S. LaCasce Post-transplant lymphoproliferative disorders. Oncologist, June 1, 2006; 11(6): 674 - 680. [Abstract] [Full Text] [PDF]

				T. G. Gross, J. C. Bucuvalas, J. R. Park, T. C. Greiner, S. H. Hinrich, S. S. Kaufman, A. N. Langnas, R. A. McDonald, F. C. Ryckman, B. W. Shaw, et al. Low-Dose Chemotherapy for Epstein-Barr Virus-Positive Post-Transplantation Lymphoproliferative Disease in Children After Solid Organ Transplantation J. Clin. Oncol., September 20, 2005; 23(27): 6481 - 6488. [Abstract] [Full Text] [PDF]

				D. P. Beynet, S. A. Wee, S. S. Horwitz, S. Kohler, S. Horning, R. Hoppe, and Y. H. Kim Clinical and Pathological Features of Posttransplantation Lymphoproliferative Disorders Presenting With Skin Involvement in 4 Patients Arch Dermatol, September 1, 2004; 140(9): 1140 - 1146. [Abstract] [Full Text] [PDF]

				K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Oncologist, February 1, 2003; 8(1): 83 - 98. [Abstract] [Full Text] [PDF]

				V. Leblond, N. Dhedin, M.-F. M. Bruneel, S. Choquet, O. Hermine, R. Porcher, S. N. Quoc, F. Davi, F. Charlotte, R. Dorent, et al. Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders J. Clin. Oncol., February 1, 2001; 19(3): 772 - 778. [Abstract] [Full Text] [PDF]

				L. J. Swinnen Post-transplant Lymphoproliferative Disorders: Implications for Acquired Immunodeficiency Syndrome-Associated Malignancies J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 38 - 43. [Abstract] [Full Text] [PDF]

				M-F. Mamzer-Bruneel, C. Lome, E. Morelon, V. Levy, P. Bourquelot, F. Jacobs, A. Gessain, E. Mac Intyre, N. Brousse, H. Kreis, et al. Durable Remission After Aggressive Chemotherapy for Very Late Post-Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center J. Clin. Oncol., November 1, 2000; 18(21): 3622 - 3632. [Abstract] [Full Text] [PDF]

				P. J. Pickhardt, M. J. Siegel, R. J. Hayashi, and M. Kelly Posttransplantation Lymphoproliferative Disorder in Children: Clinical, Histopathologic, and Imaging Features Radiology, October 1, 2000; 217(1): 16 - 25. [Abstract] [Full Text]

				B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11 (90001): S1 - S86. [Abstract] [Full Text] [PDF]

				K. W. Rosbe, A. R. Perez-Atayde, D. W. Roberson, and M. Kenna Quiz Case 1 Arch Otolaryngol Head Neck Surg, September 1, 2000; 126(9): 1153 - 1158. [Full Text] [PDF]

				S. M. Levine, L. Angel, A. Anzueto, I. Susanto, J. I. Peters, E. Y. Sako, and C. L. Bryan A Low Incidence of Posttransplant Lymphoproliferative Disorder in 109 Lung Transplant Recipients Chest, November 1, 1999; 116(5): 1273 - 1277. [Abstract] [Full Text] [PDF]

				M. Benkerrou, J.-P. Jais, V. Leblond, A. Durandy, L. Sutton, P. Bordigoni, J. L. Garnier, J. Le Bidois, F. Le Deist, S. Blanche, et al. Anti-B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome Blood, November 1, 1998; 92(9): 3137 - 3147. [Abstract] [Full Text] [PDF]

				H. J. Deeg and G. Socie Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers Blood, March 15, 1998; 91(6): 1833 - 1844. [Full Text] [PDF]

				R. M. Stone, E. J. Mark, and J. A. Ferry Case 31-1997- A 67-Year-Old Renal-Transplant-Recipient with Anemia, Leukopenia, and Pulmonary Lesions N. Engl. J. Med., October 9, 1997; 337(15): 1065 - 1074. [Full Text] [PDF]